AbbVie Inc. $ABBV Shares Bought by Capital Investment Advisors LLC

Capital Investment Advisors LLC increased its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 313,064 shares of the company's stock after purchasing an additional 7,114 shares during the quarter. AbbVie accounts for about 1.1% of Capital Investment Advisors LLC's investment portfolio, making the stock its 24th largest holding. Capital Investment Advisors LLC's holdings in AbbVie were worth $71,532,000 at the end of the most recent quarter.Quiet Outperformance From an Overlooked Dividend ETFSeveral other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. Evolution Wealth Management Inc. acquired a new position in AbbVie in the second quarter worth $26,000. Chelsea Counsel Co. bought a new stake in shares of AbbVie during the third quarter valued at about $26,000. Texas Capital Bancshares Inc TX acquired a new position in shares of AbbVie during the third quarter valued at approximately $31,000. Caitlin John LLC acquired a new position in shares of AbbVie during the 3rd quarter valued at $33,000. Finally, Delos Wealth Advisors LLC acquired a new stake in AbbVie during the second quarter valued at approximately $39,000. 70.23% of the stock is owned by institutional investors and hedge funds. Insider Buying and SellingIn other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the firm's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.25% of the stock is owned by insiders. AbbVie News RoundupThese 3 Cash Flow Machines Provide Stability in Uncertain MarketsHere are the key news stories impacting AbbVie this week: Positive Sentiment: Company outlook and dividend expectations — Analysts and commentators highlight AbbVie’s strong 2026 guidance and the likelihood of future dividend increases, driven by cash flow from Humira/Imbruvica/oncology and growth in the dermatology portfolio; that narrative supports income investors and dividend yield buyers. AbbVie: Strong 2026 Outlook, Expect Dividend Increases Positive Sentiment: Clinical and real‑world data boost dermatology franchise — AbbVie announced new clinical and real‑world evidence for risankizumab (psoriasis/psoriatic arthritis) and upadacitinib (atopic dermatitis), plus Phase‑3 data for vitiligo and alopecia areata to be presented at AAD 2026. Strong safety/efficacy reads can support durable revenue and reduce investor uncertainty around launches. AbbVie to Highlight New Clinical and Real-World Evidence... Positive Sentiment: Analyst estimate tweak — Erste Group modestly raised its FY2027 EPS estimate for AbbVie, signaling incremental confidence in earnings power (small change but supportive vs. downside fears). MarketBeat AbbVie Profile Neutral Sentiment: Allergan Aesthetics (AbbVie unit) scientific presence — Allergan is presenting multiple evidence‑based posters and product positioning (JUVÉDERM, HA injectables) at AMWC, reinforcing aesthetics growth and brand leadership but with limited immediate revenue impact. Allergan Aesthetics Reinforces Scientific Differentiation... Neutral Sentiment: Dividend yield framing for investors — Retail‑focused pieces (The Motley Fool) calculate how many ABBV shares generate targeted dividend income; useful for income investors but not an earnings catalyst. Here's How Many Shares of AbbVie (ABBV) Stock You'd Need... Negative Sentiment: Recent price weakness & value debate — Coverage noting recent share‑price declines and questions about valuation may pressure sentiment in the short term; headline focus on near‑term multiple compression can spur selling even as fundamentals are debated. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness? Analyst Ratings ChangesABBV has been the topic of a number of recent analyst reports. Citigroup cut their price target on shares of AbbVie from $235.00 to $230.00 and set a "neutral" rating on the stock in a report on Tuesday, January 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Piper Sandler lifted their price objective on AbbVie from $289.00 to $299.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 18th. Royal Bank Of Canada initiated coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 price target on the stock. Finally, UBS Group dropped their price objective on shares of AbbVie from $240.00 to $230.00 and set a "neutral" rating for the company in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $253.15.AbbVie’s Prognosis: The February Dip Looks Like a Buy SignalGet Our Latest Stock Report on ABBVAbbVie Price PerformanceAbbVie stock opened at $209.46 on Friday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company's 50-day moving average is $221.96 and its 200-day moving average is $224.52. The firm has a market capitalization of $370.37 billion, a PE ratio of 88.76, a P/E/G ratio of 0.73 and a beta of 0.34. AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the prior year, the business earned $2.16 EPS. AbbVie's quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 EPS for the current year. AbbVie Dividend AnnouncementThe business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is currently 293.22%. AbbVie Company Profile (Free Report)AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas. AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.Read MoreFive stocks we like better than AbbVieThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in AbbVie Right Now?Before you consider AbbVie, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here